Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Details)

v3.19.1
Segment Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Revenues $ 284,164 $ 307,913  
Depreciation and amortization 139,131 123,379  
Interest expense 27,641 236,986  
Net loss (4,504,929) (1,550,969)  
Identifiable long-lived tangible assets 8,249,959   $ 8,129,440
Real property operating [Member]      
Revenues 266,626 296,623  
Depreciation and amortization 40,781 32,624  
Interest expense 24,658 236,986  
Net loss 98,689 237,700  
Identifiable long-lived tangible assets 7,868,781   7,898,224
Medical related consulting services-related parties [Member]      
Revenues 14,260  
Depreciation and amortization 2,940 4,006  
Interest expense  
Net loss 190,070 100,132  
Identifiable long-lived tangible assets 4,066   6,852
Development services and sales of developed products [Member]      
Revenues 3,278 11,290  
Depreciation and amortization 95,410 86,749  
Interest expense  
Net loss 247,782 173,474  
Identifiable long-lived tangible assets 377,112   $ 224,364
Other [Member]      
Interest expense [1] 2,983  
Net loss [1] $ 3,968,388 $ 1,039,663  
[1] The Company does not allocate any interest expense and general and administrative expense of its being a public company activities to its reportable segments as these activities are managed at a corporate level.